A 45-year-old man with obesity and newly diagnosed T2DM (A1C 8.9%), ASCVD risk 14%, and eGFR 75. After metformin, which agent is preferred to reduce M...

Question

A 45-year-old man with obesity and newly diagnosed T2DM (A1C 8.9%), ASCVD risk 14%, and eGFR 75. After metformin, which agent is preferred to reduce MACE?

Accepted Answer

GLP-1 receptor agonist with proven CV benefit

Answer

Sulfonylurea

Answer

DPP-4 inhibitor

Answer

Basal insulin first

Answer

Acarbose

us-abim MCQ (SBA): Type 2 Diabetes CV Risk

A 45-year-old man with obesity and newly diagnosed T2DM (A1C 8.9%), ASCVD risk 14%, and eGFR 75. After metformin, which agent is preferred to reduce MACE?